Message

In the field of biomedicine, blockbusters that represent significant steps forward in terms of drug treatment for autoimmune diseases, cancer, chronic illnesses, and other diseases are being created one after another. Through the introduction of these biologic medical products, there is now hope for complete remission and complete cures for various illnesses that had been difficult to treat using low-molecular-weight medicine.

On the other hand, biologic medical products have high drug prices because of the costs required for their development and manufacturing. As a result, there are illnesses that have annual health care costs of several million yen per patient. This has become a social problem, as the sudden increase in these costs is affecting people’s livelihoods.

The emergence of biosimilars, which are follow-on biologic medical products, has attracted attention, as they can greatly contribute to the reduction of health care costs through the reduction of drug prices.

Chemical Bio Research (CBR) K.K. is a company that develops biosimilars. Many companies in Japan and overseas engage in the development of biosimilars and they are competing with each other over how quickly they can make it to market. Given these circumstances, we would like to contribute to health care in Japan by taking on the challenges of assessing fields with unmet demand, selecting partners that are sure to provide steady supplies, and receiving approval as early as possible.